Source: Healio News
CHICAGO — A novel chimeric antigen receptor T-cell therapy has elicited objective responses among the first eight patients who received the treatment, according to results from the phase 1 POLARIS trial presented at ASCO Annual Meeting.
Use of OriCAR-017 (Oricell Therapeutics) — an autologous, gene edited, GPRC5D-directed CAR T-cell therapy — resulted in a manageable safety profile and “impressive efficacy in [patients with] relapsed or refractory multiple myeloma,” He Huang, MD, PhD, and colleagues of Zhejiang University School of Medicine in China, wrote.